Friday, April 19, 2024
AtriCure, Inc, a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, has recently unveiled the cryoSPHERE®+. This new device utilizes advanced insulation technology to reduce freeze times by 25% compared to cryoablation probe.
AtriCure’s previous cryoSHPERE® device. Currently, the product is in an extended limited launch period in the United States, with a full launch anticipated by the end of the second quarter.
This innovation is poised to enhance patient care, improve outcomes, and empower physicians with greater procedural ease and confidence. Over the past five years, our pain management franchise has made significant strides, and with this launch, we aim to serve even more patients.”
Part of the cryoICE® platform, cryoSPHERE+ builds upon the proven safety and efficacy of its predecessor, cryoSPHERE, which received FDA clearance in November 2018 and has been used in over 60,000 procedures.
The cryoSPHERE+ is cleared by the FDA for temporarily blocking pain in adult patients through peripheral nerve ablation, as well as in adolescent patients (12-21 years old) via intercostal nerve ablation under direct visualization. Its innovative technology minimizes thermal loss by concentrating energy at the ball tip, facilitating quicker attainment of therapeutic temperature and resulting in a 25% reduction in freeze time, consequently decreasing operative duration.
Recent statistics from The Society of Thoracic Surgeons highlight the prevalence of opioid addiction as a post-operative complication, affecting 14% of lung surgery patients.
AtriCure’s cryoICE platform addresses this issue by employing a distinctive freezing technique to interrupt pain signal transmission for several months. Consequently, physicians are integrating Cryo Nerve Block therapy utilizing cryoSPHERE into their comprehensive pain management strategies.
Source: atricure.com
